Weekly paclitaxel in elderly patients (aged ≤ 70 years) with advanced non-small-cell lung cancer: An alternative choice? Results of a phase II study

Clinical Lung Cancer

Volumn 9, Issue 5, 2008, Pages 280-284

  Rossi, David ^a   Dennetta, Donatella ^a   Ugolini, Marcello ^a   Alessandroni, Paolo ^a   Catalano, Vincenzo ^a   Fedeli, Stefano Luzi ^a   Giordani, Paolo ^a   Casadei, Virginia ^a   Baldelli, Anna Maria ^a   Graziano, Francesco ^a   Catalano, Giuseppina ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Asthenia; Gemcitabine; Third generation regimen; Vinorelbine

Indexed keywords

GEMCITABINE; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG SAFETY; ELDERLY CARE; FEMALE; HISTOLOGY; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; RASH; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 54249087033     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.043     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997; 33:2313-4.
3. Havlik RJ, Yancik R, Longo S, et al. The National Cancer Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis in the elderly. Cancer 1994; 74(suppl 7):2101-6.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised trials. BMJ 1995; 311:899-909.
5. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer: update 2003. J Clin Oncol 2004; 22:330-53.
6. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005; 23:3125-37.
7. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
8. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-72.
9. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24:3657-63.
10. Socinsky MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. The Oncologist 1999; 4:408-16.
11. Lopes NM, Adams EF, Pitts TW, et al. Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cancer cell lines. Cancer Chemother Pharmacol 1993; 32:235-42.
12. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62:6938-43.
13. Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7:3942-9.
14. Garbo L, Marsland T, Garfield D, et al. A phase II study of weekly paclitaxel (Taxol) in stage IIIB, IV or relapsed after local therapy, non-small cell lung cancer (NSCLC) patients with a performance status of 2 and/or ≤ 70 years of age, with Paraplatin administered at disease progression. Proc Am Soc Clin Oncol 2001; 20:267b (Abstract 2821).
15. West W, Birch R, Sysel I, et al. A phase II trial of weekly paclitaxel in elderly patients or those with decreased performance status with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:258b (Abstract 2782).
16. Nakamura Y, Sekine I, Furuse K, et al. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusion of paclitaxel for patients aged 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol 2000; 46:114-8.
17. Massutì B, Camps C, Barcelò JR, et al. Weekly paclitaxel in non-small cell lung cancer (NSCLC): Results in older or frail patients. A Spanish Lung Cancer Group Trial (GECP 00-02). Proc Am Soc Clin Oncol 2004; 23:734 (Abstract 8044).
18. Juan O, Albert A, Campos JM, et al. Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel. Acta Oncol 2007; 46:367-73.